查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1375907

陰道炎治療藥物的市場規模、佔有率和趨勢分析報告：按疾病類型、產品、地區和細分市場預測，2023-2030年

Vaginitis Therapeutics Market Size, Share & Trends Analysis Report By Disease Type (Anti-fungal, Anti-bacterial, Hormone), By Product (OTC, Prescription), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 75 Pages | 商品交期: 2-10個工作天內

價格

陰道炎治療藥物市場成長與趨勢：

根據Grand View Research, Inc.最新報告，預計到2030年，全球陰道炎治療市場規模將達到60億美元，2023年至2030年年複合成長率為8.3%。

政府和非政府組織為提高婦女意識層級而做出的支持配合措施正在推動對陰道炎藥物的需求。據估計，飲酒消費量的增加也刺激了這些藥物的採用。美國約有 530 萬名女性面臨與健康和整體福祉相關的風險。

此外，陰道炎治療藥物研發活動的增加預計將加速市場成長。由美國過敏和感染疾病研究所 (NIAID) 資助的研究發現了有關酵母菌發育行為的重要資料，這可能會導致酵母菌感染疾病的新治療方法。此外，主要企業推出新藥預計將推動市場成長。例如，2017 年 9 月，Symbiomix Therapeutics 的 Solosec（塞克硝唑）獲得 FDA核准，這是一種治療細菌性陰道炎的藥物。

陰道炎治療藥物市場報告亮點

  • 由於產品種類繁多以及細菌性陰道病病例數量不斷增加，抗菌藥物細分市場將在 2022 年以 37.9% 的銷售佔有率引領陰道炎治療藥物市場。
  • 由於研發線產品的存在和產品採用率的增加，預計荷爾蒙在預測期內將以 8.4% 的年複合成長率實現良好成長。
  • 由於處方藥的高效性和安全性以及針對嚴重和復發性陰道炎的多種藥物的可用性，處方藥細分市場在 2022 年以 51.2% 的最大銷售佔有率引領市場。
  • 由於 FDA 對輕度陰道炎治療的核准不斷增加，成藥領域預計未來年度將以 8.7%的年複合成長率擴張。
  • 由於優質的醫療服務和陰道炎患者數量的增加，北美地區在 2022 年將佔銷售額的 38.3%。
  • 預計亞太地區將呈現最快的成長，在預測期內年複合成長率約為 9.5%。這一成長得益於積極的政府配合措施、可支配所得的增加以及龐大的目標人口。

目錄

第1章 調查方法與範圍

第2章 執行摘要

第3章 陰道炎治療藥物市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 普及和成長前景圖
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 陰道炎治療藥物市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章 治療藥物市場：疾病類型估計及趨勢分析

  • 陰道炎治療藥物市場：有關疾病類型的要點
  • 陰道炎治療藥物市場：2022年和2030年疾病類型趨勢和市場佔有率分析
  • 抗真菌劑
  • 抗菌的
  • 荷爾蒙

第5章 陰道炎治療藥物市場：產品估算與趨勢分析

  • 陰道炎治療藥物市場：產品要點
  • 陰道炎治療藥物市場：2022年和2030年產品趨勢和市場佔有率分析
  • 在商店
  • 處方箋

第6章 陰道炎治療藥物市場：區域估計與趨勢分析

  • 區域展望
  • 按地區分類的陰道炎治療藥物市場：要點
  • 北美洲
    • 2018-2030 年市場估計與預測
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 市場參與企業分類
    • Symbiomix Therapeutics LLC.
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Bayer AG
    • Janssen Pharmaceuticals Inc.
    • Lupin Pharmaceuticals Inc.
    • Lumavita AG
    • Mission Pharmacal Company
Product Code: GVR-2-68038-604-2

Vaginitis Therapeutics Market Growth & Trends:

The global vaginitis therapeutics market size is expected to reach USD 6.0 billion by 2030, registering a CAGR of 8.3% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Supportive initiatives by government and non-government agencies to increase awareness level among women is driving the demand for vaginitis drugs. Increased consumption of alcohol is also estimated to fuel the adoption of these drugs. Around 5.3 million women in the U.S. are at risk related to health and general well-being.

Furthermore, rising R&D activities for vaginitis therapeutics is anticipated to accelerate the market growth. National Institute of Allergy and Infectious Diseases (NIAID)-funded research has discovered various important data about yeast generative behavior, which could result in new way of treatment for yeast infections. In addition, introduction of new drugs by key companies is expected to propel the market growth. For instance, in September 2017, Symbiomix Therapeutics received FDA approval for Solosec (secnidazole) for the treatment of bacterial vaginosis.

Vaginitis Therapeutics Market Report Highlights:

  • Anti-bacterial segment led the market for vaginitis therapeutics with a revenue share of 37.9% in 2022 owing to the availability of a wide product range and higher number of cases of bacterial vaginosis disease
  • Hormone is expected to witness lucrative growth with a CAGR of 8.4% over the forecast period due to the presence of pipeline products and rising adoption of products
  • The prescription segment led the market with the largest revenue share of 51.2% in 2022, owing to the higher efficacy and safety of prescribed drugs and availability of a wide range of drugs for severe and recurring vaginitis
  • Over the counter segment is expected to expand at a CAGR of 8.7% in the coming years due to increasing number of FDA approvals for the treatment of mild vaginitis
  • North America dominated the market with a revenue share of 38.3% in 2022, in terms of revenue, owing to of high-quality healthcare services and increasing cases of vaginitis
  • Asia Pacific is estimated to witness the fastest growth, with a CAGR of around 9.5% over the forecast period. This growth is attributed to favorable government initiatives and rising disposable income along with the presence of a large target population base.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Disease Type
    • 1.1.2. Product
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Disease Type outlook
    • 2.2.2. Product outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Vaginitis Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Vaginitis Therapeutics Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's Five Forces
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Vaginitis Therapeutics Market: Disease Type Estimates & Trend Analysis

  • 4.1. Vaginitis Therapeutics Market: Disease Type Key Takeaways
  • 4.2. Vaginitis Therapeutics Market: Disease Type Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Anti-fungal
    • 4.3.1. Anti-fungal market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Anti-bacterial
    • 4.4.1. Anti-bacterial market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Hormone
    • 4.5.1. Hormone market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Vaginitis Therapeutics Market: Product Estimates & Trend Analysis

  • 5.1. Vaginitis Therapeutics Market: Product Key Takeaways
  • 5.2. Vaginitis Therapeutics Market: Product Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Over-the-counter
    • 5.3.1. Over-the-counter market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Prescription
    • 5.4.1. Prescription market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Vaginitis Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Vaginitis Therapeutics Market by Region: Key Takeaways
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Denmark
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Norway
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Symbiomix Therapeutics LLC.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Merck & Co., Inc.
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Pfizer Inc.
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Novartis AG
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Teva Pharmaceutical Industries Ltd.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Bayer AG
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Janssen Pharmaceuticals Inc.
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Lupin Pharmaceuticals Inc.
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Lumavita AG
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. Mission Pharmacal Company
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 3 North America vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America vaginitis therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 6 U.S. vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 7 Canada vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 8 Canada vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 9 Europe vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 10 Europe vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 11 Europe vaginitis therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 12 Germany vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 13 Germany vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 14 UK vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 15 UK vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 16 France vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 17 France vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 18 Italy vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 19 Italy vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 20 Spain vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 21 Spain vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 22 Sweden vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 23 Sweden vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 24 Norway vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 25 Norway vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 26 Denmark vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 27 Denmark vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific vaginitis therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 31 China vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 32 China vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 33 Japan vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 34 Japan vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 35 India vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 36 India vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 37 Australia vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 38 Australia vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 39 Thailand vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 40 Thailand vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 41 South Korea vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 42 South Korea vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 43 Latin America vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 44 Latin America vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 45 Latin America vaginitis therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 46 Brazil vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 47 Brazil vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 48 Mexico vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 49 Mexico vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 50 Argentina vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 51 Argentina vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 53 Middle East and Africa vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 54 Middle East and Africa vaginitis therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 55 South Africa vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 56 South Africa vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 59 UAE vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 60 UAE vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 61 Kuwait vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 62 Kuwait vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Vaginitis Therapeutics: Market outlook
  • Fig. 9 Vaginitis Therapeutics: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Vaginitis Therapeutics market driver impact
  • Fig. 15 Vaginitis Therapeutics market restraint impact
  • Fig. 16 Vaginitis Therapeutics market strategic initiatives analysis
  • Fig. 17 Vaginitis Therapeutics market: Disease type movement analysis
  • Fig. 18 Vaginitis Therapeutics market: Disease type outlook and key takeaways
  • Fig. 19 Anti-fungal market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 20 Anti-bacterial market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 21 Hormone market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 22 Vaginitis Therapeutics market: Product movement analysis
  • Fig. 23 Vaginitis Therapeutics market: Product outlook and key takeaways
  • Fig. 24 Over-the-counter market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 25 Prescription (Rx) market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 26 Global Vaginitis Therapeutics market: Regional movement analysis
  • Fig. 27 Global Vaginitis Therapeutics market: Regional outlook and key takeaways
  • Fig. 28 North America market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 29 U.S. market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 30 Canada market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 31 Europe market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 32 UK market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 33 Germany market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 34 France market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 35 Italy market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 36 Spain market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 37 Sweden market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 38 Norway market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 39 Denmark market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 40 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 41 Japan market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 42 China market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 43 India market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 44 Australia market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 45 Thailand market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 46 South Korea market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 47 Latin America market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 48 Brazil market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 49 Mexico market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 50 Argentina market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 51 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 52 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 53 South Africa market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 54 UAE market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 55 Kuwait market estimates and forecasts, 2018 - 2030 (USD Billion)